DZD8586+R-CHOP

Small molecule

DZD8586+R-CHOP is one of 43 small molecule programs targeting Diffuse Large B-Cell Lymphoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diffuse Large B-Cell LymphomaActive, not recruiting

Diffuse Large B-Cell LymphomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Eloxatin

17 3

Rayos

RRoxane Laboratories

Phase 3

57 4

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

29 5

COLUMVI

Roche

Phase 3

10 6

Cytosar

Teva

Phase 3

9 7

Vepesid

AAvyxa

Phase 3

22 8

Adcetris

Pfizer

Phase 3

6 9

Adriamycin

GGynecologic Oncology Group

Imbruvica

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1/2Recruiting

Diffuse Large B-Cell Lymphoma

NCT07059650

Clinical

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

Recruiting·DDizal Pharmaceuticals·Phase 1/2·NCT07059650·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DZD8586+R-CHOP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD8586+R-CHOP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD8586+R-CHOP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: DDizal Pharmaceuticals

DZD8586+R-CHOP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Diffuse Large B-Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News